European Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 117754 - 117754
Published: May 1, 2025
Language: Английский
Advanced Materials, Journal Year: 2024, Volume and Issue: 36(33)
Published: June 17, 2024
The development of bioorthogonal activation in drug release represents a promising avenue for precise and safe anticancer treatment. However, two significant limitations currently hinder their clinical application: i) the necessity separate administration precursor its corresponding activator, leading to poor accumulation potential side effects; ii) reliance on exogenous metal or organic activators triggering activation, which often exhibit low efficiency systemic toxicity when extending living animals. To overcome these limitations, nitric oxide (NO)-mediated codelivery nanoassembly, termed TTB-NH
Language: Английский
Citations
9
Advanced Healthcare Materials, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 19, 2025
Abstract The rational design of self‐assembled compounds is crucial for the highly efficient development carrier‐free nanomedicines. Herein, based on computer‐aided strategies, important physicochemical properties are identified to guide compounds. Then, pharmacophore hybridization strategy used self‐assemble nanoparticles by preparing new chemical structures combining groups different bioactive Hydroxychloroquine grafted with lipophilic vitamin E succinate and then co‐assembled bortezomib fabricate nanoparticle. nanoparticle can reduce M2‐type tumor‐associated macrophages (TAMs) through lysosomal alkalization induce immunogenic cell death (ICD) nuclear factor‐κB (NF‐κB) inhibition in tumor cells. In mouse models, decreased levels TAMs, regulatory T cells, transforming growth factor‐β (TGF‐β), increase proportion cytotoxicity lymphocytes. Additionally, secretion Interleukin‐6 (IL‐6) inhibiting NF‐κB enhance programmed ligand‐1 (PD‐L1) checkpoint blockade therapy. hybridization‐derived provides a dual‐modulation reprogram microenvironment, which will efficiently chemoimmunotherapy against triple‐negative breast cancer.
Language: Английский
Citations
0
Drug Resistance Updates, Journal Year: 2025, Volume and Issue: unknown, P. 101208 - 101208
Published: Jan. 1, 2025
Language: Английский
Citations
0
Nanoscale, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy characterized by limited treatment options and poor prognosis. Nanoparticle-based drug delivery systems have emerged as a promising strategy to enhance cancer therapy efficacy improving targeting, reducing toxicity, enabling multifunctional applications. This review highlights some key types of nanoparticles, including liposomes, polymeric metallic dendrimers, quantum dots, which could effectively improve the various drugs used in chemotherapy, radiotherapy, immunotherapy, offering more precise effective options. With ability stability overcome biological barriers, nanoparticle-based represent transformative for ESCC treatment. Despite challenges, such biocompatibility scalability, future holds great promise, particularly development personalized nanomedicine novel therapeutic approaches targeting tumor microenvironment. ongoing advancements, hold immense potential revolutionize patient outcomes.
Language: Английский
Citations
0
Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)
Published: April 26, 2025
Language: Английский
Citations
0
International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: unknown, P. 143052 - 143052
Published: April 1, 2025
Language: Английский
Citations
0
Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: 514, P. 163228 - 163228
Published: April 30, 2025
Language: Английский
Citations
0
European Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 117754 - 117754
Published: May 1, 2025
Language: Английский
Citations
0